Background: Profiling of targetable oncogenic drivers has significantly improved outcomes in patients with nonesmall cell lung cancer (NSCLC). About 40% of individuals with metastatic lung adenocarcinomas may benefit from personalized treatment with kinase inhibitors. There is limited data of the distribution of oncogenic drivers other than ALK and EGFR in our region. In this study we performed next generation sequence (NGS) to study the distribution of molecular alterations in patients with advanced lung cancer. Herein we present preliminary data of a single center experience. Method: A prospective, single-center, observational study was conducted. We included 125 patients > 18 years old with NSCLC from 06/2015 to 06/2018. NGS was performed with DNA/RNA from formalin-fixed, paraffin-embedded (FFPE) tumor tissue with OncomineTM Focus Assay (Ion 520 Chip), sequenced in Ion S5 Next Generation Sequencing Systems, analyzed with Ion ReporterTM Software 5.2.1 and informed with Ion TorrentTM OncomineTM Knowledgebase Reporter. Results were compared with those from standard pathology and molecular biology techniques, when available, like immunohistochemistry (IHQ) and FISH for ROS1 and ALK and PCR and sequencing for EGFR. We report partial results from the first 51 patients included. Results: Median (IQR) age was 65 years (59-74), n¼28 were men (55%), smoker/former-smoker/non-smoker n¼11 (21.6%)/ n¼31 (60.8%)/ n¼9 (17.6%), Stage IIIa n¼7 (13.7%), IIIb n¼6 (11.8%), IV n¼38 (74.5%). Adenocarcinoma histology n¼43 (84.3%). Assay performance was 100% for DNA analysis and 60.8% for the study of fusions and CNV from RNA. Distribution of molecular alterations: KRAS n¼18 (35%), EGFR n¼8 (17.6%) BRAF n¼2 (4%), METex14 skipping n¼2 (4%), HER2 n¼1 (2%), ALK rearrangements n¼5 (10%) y ROS1 rearrangements n¼2 (4%). Co-mutations: EGFR+BRAF n¼1, ALK+KRAS n¼1, KRAS+AKT n¼1. Conclusion: NGS allows to optimize the molecular profiling of tumors from patients with lung cancer in our population. It can simultaneously identify mutations, rearrangements and alternative splicing events in key oncogenic drivers that can select patients to treatment with kinase inhibitors, currently available in the daily practice and in clinical development. Keywords: Next Generation Sequencing, nonesmall cell lung cancer, Molecular profiling, Targetable Hospital Beatriz Ângelo, Lisbon/PT Background: Lung cancer is the leading cause of cancer-related mortality worldwide and its incidence continues to rise. Overall survival remains low, hence the importance of accurate staging and approach. When indicated, surgical resection remains the gold standard. Our aim was to compare outcomes in surgical patients of a district hospital with those described in the literature. Method: Data was collected retrospectively from March 2012 to December 2017 and analyzed using MS Excel. All patients were evaluated in a multidisciplinary board. Patients operated for diagnostic purpose were excluded. Results: Out of 488 patients diagnosed with lung cancer, 101 surgeries were performed, regarding 88 patients. Mean age was 63,5 (±9,4) and 68% were male. Smoking habits were present in 77% of patients, COPD and enphysema in 19%, diabetes mellitus in 14% and previous lung cancer in 1 patient. Adenocarcinoma (71%) was the most frequent tumor. Concerning pathological stage, 54% of patients were stage IA or IB. 23% were operated after neoadjuvant treatment. 71% of patients were submitted to lobectomy with systematic lymph node dissection and 14% to wedge resection. 41% of cases were approached using VATS techniques. Adjuvant chemotherapy, radiotherapy and chemotherapy plus radiotherapy were indicated in 34%, 4% and 9% of cases, respectively.
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Perioperative mortality was 0,9% (1 case) and 10,9% had complications, pneumonia being the most frequent. Mean follow-up time was 31 months (±16 Background: We present demographic and disease characteristics for the first interim analysis of ASTRIS study in Argentina. Method: ASTRIS is a Phase III open-label, single-arm, multi-national, real world treatment (RWT) study assessing the efficacy and safety of osimertinib in patients with advanced T790M mutation positive nonesmall cell lung cancer (NSCLC), who have previously received an EGFR-TKI. Key inclusion criteria are adults with locally advanced or metastatic NSCLC having a confirmed T790M mutation who received a prior EGFR-TKI and have WHO performance status 0 À 2. T790M status must be confirmed by an appropriately validated test. Patients with asymptomatic CNS (central nervous system) metastases are allowed. Patients receive Osimertinib 80 mg once daily for as long as the patient continues to receive clinical benefit, as judged by the investigator. Results: Argentina enrolled 29 patients from three centers. At data cut-off (20 Oct 2017) 25 patients (78,1%) were still ongoing, 4 patients had died. Median follow up 3,3 months (0-8). The mean age was 59.6 years (35-91); 72,4% (21) were less than 65 years old; 82,8% females; 96,6% Caucasian; ECOG 0-1 65,5%, ECOG 2 20,7%. Stage IV 89,7%. Previous cancer therapies included gefitinib 37,9%, erlotinib 31% and afatinib 37,9%. 48,3% of the patients had received previous chemotherapy, 6,9% previous immunotherapy and 31% previous radiotherapy. Only patients with T790M positive were enrolled in this study, 27,6% (8) had tissue biopsy at progression; 65,5% (19) were diagnosed by plasma sample [FT1] [BP2] , 3,4% (1) by cytology and 3,4% (1) after bone marrow biopsy. The origin of the biopsy tissue was primary tumor in 87,5% and metastasis in 12,5%. T790M mutation was found in all the patients. T790M alone in 72,4% (21) and in combination with other EGFR mutations in 27,6% (8) [FT3] . The other EGFR mutations were exon 19 deletion 20,7%; exon 20 insertion 6,9% and L858R 6,9%. Testing methods: Roche Cobas 1; Qiagen Therascreen 16; Entrogen EGFR kit 3, sanger sequencing 1, ddPCR 7, unknown 1. Conclusion: We present real word evidence data of demographics and diagnostic patterns of patients beyond progression. Efficacy data is still immature and will be presented in subsequent interim analysis. Keywords: T790M EGFR, Advanced lung cancer, osimertinib, Astris Real Word Evidence Trial
